Relapsed or Refractory Classical Hodgkin's Lymphoma

DBCOND0125653Hemic and Lymphatic DiseasesImmunoproliferative Disorders

Relapsed or Refractory Classical Hodgkin's Lymphoma is the indication for 1 drug in DrugBank. It is covered by 2 curated, structured indications.

Also known as
Relapsed/Refractory Classical Hodgkin's Lymphoma · Relapsed or Refractory Classical Hodgkin Lymphoma · Refractory or Relapsed Classical Hodgkin Lymphoma · Relapsed/Refractory Classical Hodgkins Lymphoma · Relapsed/Refractory Classical Hodgkin Lymphoma
Classified under
Indicated drugs

What you can answer from here — as of October 22, 2026

1Indicated drugWith each drug's targets and mechanism
Listed above
2Structured indicationsPopulation, line of therapy, route and combination as fields, not prose
Sign in
5Clinical trialsPhase, status and sponsor resolved per trial
Sign in
1Drug reporting it as an adverse effectWith incidence where the label states it
Sign in

Which approved drugs for Relapsed or Refractory Classical Hodgkin's Lymphoma share a target, and which companies have late-stage candidates against it?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In